$-0.28 EPS Expected for Oramed Pharmaceuticals Inc. (ORMP)

November 11, 2018 - By Eugene Smith

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) LogoInvestors sentiment increased to 1 in 2018 Q2. Its up 0.67, from 0.33 in 2018Q1. It improved, as 2 investors sold Oramed Pharmaceuticals Inc. shares while 2 reduced holdings. 2 funds opened positions while 2 raised stakes. 251,588 shares or 7.11% more from 234,885 shares in 2018Q1 were reported.
Blackrock Inc reported 0% stake. Jfs Wealth Advisors reported 500 shares stake. Citigroup holds 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 7,400 shares. Renaissance Technology Ltd Liability Co reported 69,800 shares or 0% of all its holdings. Pnc Gp accumulated 21,200 shares. North Carolina-based Bancorporation Of America Corp De has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Deutsche Commercial Bank Ag holds 0% or 17,605 shares. Bank Of Montreal Can has 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 2,600 shares. Wells Fargo & Mn invested 0% of its portfolio in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Glenmede Trust Na invested in 20,000 shares or 0% of the stock. Barclays Public Limited Liability Com invested in 41,186 shares or 0% of the stock. Royal Bancorp Of Canada has invested 0% in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). Morgan Stanley owns 0% invested in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) for 29,439 shares.

Since July 10, 2018, it had 1 insider buy, and 0 selling transactions for $357 activity.

Analysts expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report $-0.28 EPS on December, 5.They anticipate $0.08 EPS change or 40.00 % from last quarter’s $-0.2 EPS. After having $-0.30 EPS previously, Oramed Pharmaceuticals Inc.’s analysts see -6.67 % EPS growth. The stock decreased 0.23% or $0.01 during the last trading session, reaching $4.25. About 4,287 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 43.28% since November 11, 2017 and is downtrending. It has underperformed by 58.90% the S&P500.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $73.79 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

Another recent and important Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news was published by Prnewswire.com which published an article titled: “Oramed to Present at the Tides Europe 2018 Conference” on November 05, 2018.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.